CATHERINE COATES: Open Payments
NPI 1811441082 · SALT LAKE CITY, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$929 in 52 payments from 19 companies in 2025. Trend: 2023 $1,152 · 2024 $1,184 · 2025 $929
Food & beverage: $929
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $287 |
| PFIZER INC. | 11 | $145 |
| Corcept Therapeutics | 2 | $54 |
| Astellas Pharma US Inc | 3 | $49 |
| Amgen Inc. | 3 | $47 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Phathom Pharmaceuticals, Inc. | 2 | $34 |
| Novo Nordisk Inc | 2 | $34 |
| Hologic Sales and Service, LLC | 1 | $24 |
Products named: VRAYLAR, NURTEC ODT, UBRELVY, QULIPTA, Korlym, Veozah, CAPLYTA, REXULTI.
Industry payments across UT — which companies pay providers there.
